TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22440074

Group type: EXPERIMENTAL
Intervention: Negative mood with 'as many as can' stop rule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive mood with 'feel like continuing' stop rule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discrete negative moods
Number of subjects: 0
Study: 20406273

Group type: EXPERIMENTAL
Intervention: Home visits advising mothers about healthy feeding practices (monthly advice up to 6 months and then at 8, 10, and 12 months)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Home visits advising mothers about healthy feeding practices
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study: 18636308

Group type: EXPERIMENTAL
Intervention: Group self-management education
Number of subjects: 20
Study: 15930443

Group type: EXPERIMENTAL
Intervention: Fortified dairy product containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), oleic acid, folic acid, and vitamins A, B‐6, D, and E, 500 mL/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semiskimmed milk with added vitamins A and D, 500 mL/d
Number of subjects: 60
Study: 12885705

Group type: EXPERIMENTAL
Intervention: 18 g essential amino acids (EAA group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 40 g balanced amino acids (BAA group)
Number of subjects: 14
Study: 10400089

Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9086127

Group type: EXPERIMENTAL
Intervention: New cell culture-derived vaccinia virus vaccine administered intradermally
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: New cell culture-derived vaccinia virus vaccine administered intramuscularly
Number of subjects: 91

Group type: COMPARATOR
Intervention: Licensed vaccinia vaccine administered by scarification
Number of subjects: 91
Study: 8457081

Group type: EXPERIMENTAL
Intervention: Ticlopidine, 500 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3091205

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study: 30946276

Group type: EXPERIMENTAL
Intervention: Velocity-Based Training (VBT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Percentage-Based Training (PBT)
Number of subjects: 16
Study: 29361981

Group type: EXPERIMENTAL
Intervention: Intraoperative Brief Electrical Stimulation (BES) applied to the spinal accessory nerve (SAN) for 60 minutes at 20 Hz, 3-5 V, 0.1 msec balanced biphasic pulses.
Number of subjects: 54

Group type: COMPARATOR
Intervention: No stimulation (NS) as control group.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BES in patients with Level IIb + V neck dissections.
Number of subjects: 54
Study: 27049086

Group type: EXPERIMENTAL
Intervention: Wuzhi capsule (one capsule in the morning and evening for 3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no Wuzhi capsule)
Number of subjects: 60
Study: 24906133

Group type: COMPARATOR
Intervention: Intravenous propranolol (1 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral propranolol (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total serum bile acids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Correlation between SBA concentration and propranolol oral AUC0-∞
Number of subjects: 20
Study: 22969845

Group type: EXPERIMENTAL
Intervention: Vitamin B12 + Goshajinkigan treatment (Group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vitamin B12 treatment (Group A)
Number of subjects: 29
Study: 20594220

Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg/day
Number of subjects: 22
Study: 18315714

Group type: EXPERIMENTAL
Intervention: Semen samples from young men in Hamburg
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Semen samples from young men in Leipzig
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Combined semen samples from Hamburg and Leipzig
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Comparison of motile spermatozoa
Number of subjects: 791
Study: 15742266

Group type: EXPERIMENTAL
Intervention: Postoperative oral antibiotic treatment
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Isotonic saline irrigation
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Postoperative topical antibiotic drops
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 12093661

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (0.05 mg/ml) applied topically to the filtering bleb on days 1, 2, and 3 after surgery (postoperative application)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mitomycin-C (0.2 mg/ml) applied by means of a sponge during surgery (intraoperative application)
Number of subjects: 50
Study: 10503682

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg 8 hourly)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg at entry and again at 24 h)
Number of subjects: 46
Study: 8879982

Group type: EXPERIMENTAL
Intervention: 100 mg of standardized ginseng extract Ginsana G 115
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 227
Study: 8378107

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Placebo-TENS
Number of subjects: 42
Study: 3005152

Group type: EXPERIMENTAL
Intervention: 200 micrograms clonidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28060527

Group type: EXPERIMENTAL
Intervention: Intrinsic religiosity
Number of subjects: 2322

Group type: COMPARATOR
Intervention: Depression
Number of subjects: 2322
Study: 27040801

Group type: EXPERIMENTAL
Intervention: 13 G vacuum-assisted biopsy (VAB)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 14 G core needle biopsy (CNB)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Comparison of repeat procedure willingness
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Diagnostic yield
Number of subjects: 81
Study: 25267748

Group type: EXPERIMENTAL
Intervention: p16 positive expression in non-OPSCC
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: HPV ISH positive status in non-OPSCC
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: p16 expression for progression-free survival (PFS)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: p16 expression for overall survival (OS)
Number of subjects: 322

Group type: COMPARATOR
Intervention: p16 positive OPSCC vs p16 positive non-OPSCC
Number of subjects: 322

Group type: COMPARATOR
Intervention: p16 negative OPSCC vs p16 negative non-OPSCC
Number of subjects: 322
Study: 22541306

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU-IS)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU-OS)
Number of subjects: 201
Study: 20930100

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) consisting of up to ten 1-hour sessions within 6 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Brief nursing intervention (BNI) consisting of two 1-hour sessions, 3 months apart
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 220
Study: 17684525

Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 supplement plus 500 mg calcium (CaD group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo plus 500 mg calcium (Ca group)
Number of subjects: 102
Study: 15817918

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12028741

Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 10696277

Group type: EXPERIMENTAL
Intervention: Positive stimulus A (1,000 points) vs Negative stimulus B (0 points)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive stimulus C (100 points) vs Negative stimulus D (0 points)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive stimuli A (1,000 points) vs C (0 points)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive stimulus B (1,000 points) vs Negative stimulus D (0 points)
Number of subjects: 0
Study: 8935235

Group type: EXPERIMENTAL
Intervention: TS (Tourette syndrome)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TS/information
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TS
Number of subjects: 0
Study: 1936066

Group type: EXPERIMENTAL
Intervention: Eterobarbital (DMMP) 400 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phenobarbital (PB) 200 mg
Number of subjects: 8
Study: 7022286

Group type: EXPERIMENTAL
Intervention: VP-16-213 (etoposide) administered orally at 150 mg/m2/day for 5 days every 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: VP-16-213 (etoposide) administered intravenously at 150 mg/m2 weekly
Number of subjects: 30
Study: 30584047

Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing plus routine door-to-door HIV testing services
Number of subjects: 26973

Group type: COMPARATOR
Intervention: PopART standard of care of door-to-door HIV testing services alone
Number of subjects: 26973

Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing plus routine door-to-door HIV testing services (among men)
Number of subjects: 26973

Group type: COMPARATOR
Intervention: PopART standard of care of door-to-door HIV testing services alone (among men)
Number of subjects: 26973
Study: 29031084

Group type: EXPERIMENTAL
Intervention: Active training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Random-feedback-based training (Control)
Number of subjects: 76
Study: 26293044

Group type: EXPERIMENTAL
Intervention: Tac‐QD (tacrolimus once daily)
Number of subjects: 125
Study: 23949097

Group type: EXPERIMENTAL
Intervention: 0.5 ratio drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.8 ratio drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.25 ratio drink
Number of subjects: 12
Study: 21821622

Group type: EXPERIMENTAL
Intervention: Intensive low-energy diet (LED) with dietary consultations, 810 kcal/day during weeks 0-8 and weeks 32-36.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Minimal attention control group with dietary instruction for 2 hours at baseline, weeks 8, 32, 36, and 52.
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intensive low-energy diet (LED) with dietary consultations.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Minimal attention control group.
Number of subjects: 89
Study: 19283866

Group type: EXPERIMENTAL
Intervention: Stochastic Resonance Vibration (SRV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sinusoidal Vibration (SV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maximum Voluntary Contraction
Number of subjects: 0
Study: 17713431

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 15075539

Group type: EXPERIMENTAL
Intervention: 8-week treatment interruption followed by a six to nine-drug rescue regimen
Number of subjects: 68

Group type: COMPARATOR
Intervention: Multidrug therapy alone
Number of subjects: 68
Study: 11838566

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 50
Study: 9483586

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% ophthalmic solution (LOS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7831455

Group type: EXPERIMENTAL
Intervention: Haloperidol (neuroleptic treatment)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3417462

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent doses of buprenorphine hydrochloride (0.3 mg intramuscularly every 3 to 6 hours)
Number of subjects: 16
Study: 30957909

Group type: EXPERIMENTAL
Intervention: Kognito At Risk for College Students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained students
Number of subjects: 0
Study: 28687626

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dexamethasone to Methylprednisolone (crossover phase)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Methylprednisolone to Dexamethasone (crossover phase)
Number of subjects: 65
Study: 25222881

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg and Glycopyrronium 50 μg (combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indacaterol 150 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrronium 50 μg
Number of subjects: 0
Study: 23886280

Group type: EXPERIMENTAL
Intervention: Personal Resilience and Enrichment Programme (PREP), six weekly sessions focused on emotional awareness, expression and management, identifying roles and personal strengths, and effective problem-solving skills.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 132
Study: 20332355

Group type: EXPERIMENTAL
Intervention: Automated glucagon plus insulin delivery
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High-gain glucagon delivery
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-gain glucagon delivery
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo plus insulin
Number of subjects: 13
Study: 18836798

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiotherapy followed by chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 16278081

Group type: EXPERIMENTAL
Intervention: Intraoral mandibular repositioner appliances (IOMRAs)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (improved patients)
Number of subjects: 40
Study: 12716689

Group type: EXPERIMENTAL
Intervention: Calcium plus 10,000 U vitamin D(2)/wk
Number of subjects: 187

Group type: COMPARATOR
Intervention: Calcium supplements alone (1000 mg Ca/d)
Number of subjects: 187
Study: 11028551

Group type: EXPERIMENTAL
Intervention: Perioperative enteral immunonutrition (treatment group, n = 102)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard enteral diet (control group, n = 104)
Number of subjects: 206
Study: 8681013

Group type: EXPERIMENTAL
Intervention: Nuclear cardiology procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost effectiveness evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical methods for evaluating diagnostic tests
Number of subjects: 0
Study: 1574976

Group type: EXPERIMENTAL
Intervention: Protamine infusion
Number of subjects: 10
Study: 3897895

Group type: EXPERIMENTAL
Intervention: Oxiracetam (2 X 400 mg capsules t.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31891136

Group type: EXPERIMENTAL
Intervention: BLTR (Bilamellar Tarsal Rotation)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: PLTR (Posterior Lamellar Tarsal Rotation)
Number of subjects: 1000
Study: 29576369

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet + exercise
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet
Number of subjects: 277

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Pancreatic-fat loss
Number of subjects: 277
Study: 26303808

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care (incubator care)
Number of subjects: 100
Study: 25077916

Group type: EXPERIMENTAL
Intervention: Purified anthocyanins (320 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 22889987

Group type: EXPERIMENTAL
Intervention: Resistance training + whey supplement (RW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance training + placebo (RP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study: 19535219

Group type: EXPERIMENTAL
Intervention: Large particle-size hyaluronic acid (LPHA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Small particle-size hyaluronic acid (SPHA)
Number of subjects: 17
Study: 17442904

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin threshold of 7 g per deciliter)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin threshold of 9.5 g per deciliter)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 637

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 637
Study: 16181835

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin (60 mg/m2 intravenously) and 5-fluorouracil (1,000 mg/m2 per day) for 4 days, three cycles at 3-week intervals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 40
Study: 12909505

Group type: EXPERIMENTAL
Intervention: Premarin, 0.625 mg for 25 days monthly, with Provera, 10 mg for 10 of these 25 days (hormone therapy) for 2 years
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 10503801

Group type: EXPERIMENTAL
Intervention: Worst-rank score analysis for informatively missing observations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worst-rank score analysis
Number of subjects: 0
Study: 9012222

Group type: EXPERIMENTAL
Intervention: Golytely solution (3 litres)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clean Prep (4 litres)
Number of subjects: 150

Group type: COMPARATOR
Intervention: X-Prep with eating restriction (3 days)
Number of subjects: 150
Study: 1871737

Group type: EXPERIMENTAL
Intervention: Oat-supplemented diet (added to bread, breakfast cereals, porridge, or crispbread)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Crispbread (control group)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control groups (three groups)
Number of subjects: 5
Study: 6349668

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg once daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (all doses)
Number of subjects: 0
Study: 30654534

Group type: EXPERIMENTAL
Intervention: Mindfulness training (4 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mindlessness group (control)
Number of subjects: 0
Study: 30322501

Group type: EXPERIMENTAL
Intervention: Early drain removal (drains removed output‐based, i.e., flow less than 30 ml/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (drains removed at hospital discharge, i.e., 4-5 days after surgery)
Number of subjects: 99
Study: 26919568

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.2% in 8% low‐molecular weight dextran
Number of subjects: 54

Group type: COMPARATOR
Intervention: Levobupivacaine 0.2% in saline (control)
Number of subjects: 54
Study: 24574507

Group type: EXPERIMENTAL
Intervention: Circumferential spread of local anaesthetic (LA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-circumferential spread of local anaesthetic (LA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (circumferential and non-circumferential)
Number of subjects: 21
Study: 22251130

Group type: EXPERIMENTAL
Intervention: l-arginine (6 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 21062666

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 5425

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 5425
Study: 17397305

Group type: EXPERIMENTAL
Intervention: Platelet concentrate (PC)
Number of subjects: 20
Study: 15086925

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g per day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12066638

Group type: EXPERIMENTAL
Intervention: CerAdapt (test) abutments after 1 year
Number of subjects: 69

Group type: COMPARATOR
Intervention: CeraOne (control) abutments after 1 year
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CerAdapt (test) and CeraOne (control) abutments between 1 and 3 years
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CerAdapt (test) and CeraOne (control) abutments
Number of subjects: 69
Study: 9824172

Group type: EXPERIMENTAL
Intervention: Videotape of initial interview (experimental group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo videotape (control group)
Number of subjects: 18
Study: 8110696

Group type: EXPERIMENTAL
Intervention: Topical timolol 0.1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lingual timolol 0.1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (topical)
Number of subjects: 0
Study: 2483239

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: No antiarrhythmic drugs
Number of subjects: 3
Study: 19189

Group type: EXPERIMENTAL
Intervention: Adrenergic bronchodilator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-adrenergic therapy
Number of subjects: 0
Study: 31911130

Group type: EXPERIMENTAL
Intervention: Shanxi Dayi Hospital score (SDH score)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 776

Group type: COMPARATOR
Intervention: Wells score
Number of subjects: 776

Group type: COMPARATOR
Intervention: Revised Geneva score
Number of subjects: 776

Group type: COMPARATOR
Intervention: Wells score and Revised Geneva score
Number of subjects: 776
Study: 31567466

Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0